Discovery of Non-psychoactive Scaffolds in Cannabis Halting SARS-CoV-2 Host Entry and Replication Machinery

Overview

Journal Future Virol

Specialty Microbiology

Date 2022 Apr 11

PMID 35399958

Authors

Amira R Khattab

Mohamed Teleb

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease still poses a global health threat which advocates continuous research efforts to develop effective therapeutics. We screened out an array of 29 cannabis phytoligands for their viral spike-ACE2 complex and main protease (M) inhibitory actions by modeling to explore their possible dual viral entry and replication machinery inhibition. Physicochemical and pharmacokinetic parameters (ADMET) formulating drug-likeness were computed. Among the studied phytoligands, cannabigerolic acid , cannabigerol , and its acid methyl ether possessed the highest binding affinities to SARS-CoV-hACE2 complex essential for viral entry. Canniprene , cannabigerolic methyl ether and cannabichromene were the most promising M inhibitors. These non-psychoactive cannabinoids could represent plausible therapeutics with added-prophylactic value as they halt both viral entry and replication machinery.

Citing Articles

Establishment of a Yeast Two-Hybrid-Based High-Throughput Screening Model for Selection of SARS-CoV-2 Spike-ACE2 Interaction Inhibitors.

Li D, You B, Guo K, Zhou W, Li Y, Wang C Int J Mol Sci. 2025; 26(2.

PMID: 39859397 PMC: 11765512. DOI: 10.3390/ijms26020678.

Therapeutic Potential and Predictive Pharmaceutical Modeling of Stilbenes in .

OCroinin C, Guerra A, Doschak M, Lobenberg R, Davies N Pharmaceutics. 2023; 15(7).

PMID: 37514127 PMC: 10386382. DOI: 10.3390/pharmaceutics15071941.

Repurposing 1,2,4-oxadiazoles as SARS-CoV-2 PLpro inhibitors and investigation of their possible viral entry blockade potential.

Ayoup M, ElShafey M, Abdel-Hamid H, Ghareeb D, Abu-Serie M, A Heikal L Eur J Med Chem. 2023; 252:115272.

PMID: 36966652 PMC: 10008816. DOI: 10.1016/j.ejmech.2023.115272.

References

Singh R, Bhardwaj V, Sharma J, Purohit R, Kumar S . In-silico evaluation of bioactive compounds from tea as potential SARS-CoV-2 nonstructural protein 16 inhibitors. J Tradit Complement Med. 2021; 12(1):35-43. PMC: 8172245. DOI: 10.1016/j.jtcme.2021.05.005. View

Veber D, Johnson S, Cheng H, Smith B, Ward K, Kopple K . Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002; 45(12):2615-23. DOI: 10.1021/jm020017n. View

Shady N, Khattab A, Ahmed S, Liu M, Quinn R, Fouad M . Hepatitis C Virus NS3 Protease and Helicase Inhibitors from Red Sea Sponge () Species in Green Synthesized Silver Nanoparticles Assisted by in Silico Modeling and Metabolic Profiling. Int J Nanomedicine. 2020; 15:3377-3389. PMC: 7231760. DOI: 10.2147/IJN.S233766. View

Abassi Z, Skorecki K, Heyman S, Kinaneh S, Armaly Z . Covid-19 infection and mortality: a physiologist's perspective enlightening clinical features and plausible interventional strategies. Am J Physiol Lung Cell Mol Physiol. 2020; 318(5):L1020-L1022. PMC: 7200872. DOI: 10.1152/ajplung.00097.2020. View

Yazdanian M, Glynn S, Wright J, Hawi A . Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res. 1998; 15(9):1490-4. DOI: 10.1023/a:1011930411574. View

Lipinski C, Lombardo F, Dominy B, Feeney P . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26. DOI: 10.1016/s0169-409x(00)00129-0. View

Baqui A, Kelley J, Jabra-Rizk M, DePaola L, Falkler W, Meiller T . In vitro effect of oral antiseptics on human immunodeficiency virus-1 and herpes simplex virus type 1. J Clin Periodontol. 2001; 28(7):610-6. DOI: 10.1034/j.1600-051x.2001.028007610.x. View

Ligresti A, Moriello A, Starowicz K, Matias I, Pisanti S, De Petrocellis L . Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther. 2006; 318(3):1375-87. DOI: 10.1124/jpet.106.105247. View

Berman P, Futoran K, Lewitus G, Mukha D, Benami M, Shlomi T . A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis. Sci Rep. 2018; 8(1):14280. PMC: 6155167. DOI: 10.1038/s41598-018-32651-4. View

10.

Das S, Sarmah S, Lyndem S, Singha Roy A . An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study. J Biomol Struct Dyn. 2020; 39(9):3347-3357. PMC: 7232884. DOI: 10.1080/07391102.2020.1763201. View

11.

Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z . Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell. 2020; 181(4):894-904.e9. PMC: 7144619. DOI: 10.1016/j.cell.2020.03.045. View

12.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

13.

El Hawary S, Khattab A, Marzouk H, El Senousy A, Alex M, Aly O . identification of SARS-CoV-2 spike (S) protein-ACE2 complex inhibitors from eight species and cultivars analyzed by LC-MS. RSC Adv. 2022; 10(70):43103-43108. PMC: 9058143. DOI: 10.1039/d0ra08997d. View

14.

Khattab A, Teleb M, Kamel M . study of potential anti-SARS cell entry phytoligands from : a promising avenue for prophylaxis. Future Virol. 2021; 0(0). PMC: 8559586. DOI: 10.2217/fvl-2021-0031. View

15.

Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y . Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5):766-788. PMC: 7102550. DOI: 10.1016/j.apsb.2020.02.008. View

16.

Yee S . In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man--fact or myth. Pharm Res. 1997; 14(6):763-6. DOI: 10.1023/a:1012102522787. View

17.

Hanus L, Meyer S, Munoz E, Taglialatela-Scafati O, Appendino G . Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016; 33(12):1357-1392. DOI: 10.1039/c6np00074f. View

18.

Rossi F, Tortora C, Argenziano M, Di Paola A, Punzo F . Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?. Int J Mol Sci. 2020; 21(11). PMC: 7312493. DOI: 10.3390/ijms21113809. View

19.

Hensel A, Bauer R, Heinrich M, Spiegler V, Kayser O, Hempel G . Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature. Planta Med. 2020; 86(10):659-664. PMC: 7356065. DOI: 10.1055/a-1177-4396. View

20.

Mahdian S, Ebrahim-Habibi A, Zarrabi M . Drug repurposing using computational methods to identify therapeutic options for COVID-19. J Diabetes Metab Disord. 2020; 19(2):691-699. PMC: 7261216. DOI: 10.1007/s40200-020-00546-9. View